Bfsg LLC Has $541,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Bfsg LLC lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.1% in the fourth quarter, Holdings Channel reports. The firm owned 7,095 shares of the medical research company’s stock after selling 300 shares during the quarter. Bfsg LLC’s holdings in Edwards Lifesciences were worth $541,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. South Dakota Investment Council grew its holdings in shares of Edwards Lifesciences by 15.2% during the fourth quarter. South Dakota Investment Council now owns 257,600 shares of the medical research company’s stock worth $19,642,000 after purchasing an additional 33,896 shares during the last quarter. GAMMA Investing LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $180,000. Linden Thomas Advisory Services LLC boosted its holdings in Edwards Lifesciences by 8.1% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 7,015 shares of the medical research company’s stock valued at $535,000 after acquiring an additional 527 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Edwards Lifesciences by 17.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,125 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 164 shares during the last quarter. Finally, RWA Wealth Partners LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $238,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several recent analyst reports. Oppenheimer boosted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Stifel Nicolaus upped their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Mizuho increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Evercore ISI increased their price target on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $388,801.62. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded up $0.86 on Wednesday, hitting $88.61. The company’s stock had a trading volume of 3,234,911 shares, compared to its average volume of 3,823,988. The company has a 50-day simple moving average of $90.18 and a 200 day simple moving average of $78.62. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a market capitalization of $53.34 billion, a PE ratio of 38.14, a PEG ratio of 4.31 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $0.64 EPS. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.